NCT03242551 (BINC-B) is a Phase 2 clinical trial of Chemotherapy in Breast Neoplasms, sponsored by Shenzhen People's Hospital.

Who is sponsoring NCT03242551?

NCT03242551 is sponsored by Shenzhen People's Hospital.

What drugs are being tested in NCT03242551?

Interventions in NCT03242551: Chemotherapy.

What condition does NCT03242551 study?

NCT03242551 studies Breast Neoplasms.

Is NCT03242551 still recruiting?

NCT03242551 is currently status unknown. Last updated 14 November 2017.

Last reviewed 2017-11-14 · How we verify

NCT03242551: BINC-B

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Biomarkers Investigation of Neoadjuvant Chemotherapy for Breast Cancer

Status unknown Phase 2 Last updated 14 November 2017

What this trial tests

Phase 2 trial testing Chemotherapy in Breast Neoplasms in 120 participants. Status unknown.

Timeline

8 November 2017

Primary endpoint
31 August 2022

31 December 2022

Quick facts

Lead sponsor	Shenzhen People's Hospital
Phase	Phase 2
Status	Status unknown
Study type	INTERVENTIONAL
Design	sequential
Masking	none
Primary purpose	treatment
Enrollment	120
Start date	8 November 2017
Primary completion	31 August 2022
Estimated completion	31 December 2022
Sites	2 locations across China

Drugs / interventions tested

Chemotherapy (chemotherapy) — full drug profile →

Conditions studied

Breast Neoplasms — all drugs for Breast Neoplasms →

Sponsor

Shenzhen People's Hospital

Who can join

Adults 18 to 70, female only, with Breast Neoplasms. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The BINC-B trial is a diagnostic and interventional study in which various function imaging methods as Magnetic Resonance Imaging (PWI, DWI and DCE-MRI) and will be compared with common imaging methods (mammography and/or ultrasound) to investigate if an early response to a combined neoadjuvant chemotherapy in operable or potentially operable breast cancer. For breast cancer patients with positive HER-2, additional Herceptin could improve the response further. In this study the efficacy of combined neoadjuvant therapy with or without Herceptin should be evaluated and the role in predicting the tumor response with different imaging should be estimated.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Predicting the response to neoadjuvant therapy for early-stage breast cancer: tumor-, blood-, and imaging-related biomarkers.
Tan W, Yang M, Yang H, Zhou F, et al · · 2018 · cited 37× · PMID 30349367 · DOI 10.2147/cmar.s174435

Verify or expand the search:

Other trials of Chemotherapy

Trials testing the same drug.

NCT07391774 — Testing Whether Hormone Therapy With Ribociclib is as Effective as Chemotherapy Followed by Hormone Therapy With Ribocic · Phase 3 · not yet recruiting
NCT07476287 — Symbiotic-Lung-14: A Study to Learn About the Study Medicine Called PF08634404 in Combination With Chemotherapy in Adult · Phase 2 · recruiting
NCT07392892 — A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Gastroesophageal Cancer · Phase 2, PHASE3 · recruiting
NCT07288034 — Immunotherapy Biomarkers to Predict First-line PD(L)1-based Immunotherapy Response and Selection of Second-line Treatmen · Phase 2 · recruiting
NCT07078604 — A Cancer Vaccine (STEMVAC) in Combination With Chemotherapy for the Treatment of PD-L1 Negative Metastatic Triple-Negati · Phase 2 · recruiting

Other recruiting trials for Breast Neoplasms

Currently open trials in the same condition.

NCT07214532 — Signatera-Guided CDK4/6 Inhibitor Therapy in Breast Cancer · NA · recruiting
NCT07500428 — Construction of a Benchmark for Breast Ultrasound AI Interpretation and Performance Evaluation of Multimodal AI Models · recruiting
NCT07581834 — Efficacy and Safety of Dalpiciclib Combined With Endocrine Adjuvant Therapy for Early HR +/HER2- Breast Cancer: a Multic · Phase 2 · recruiting
NCT07222215 — PhII Randomized CAPecitabine + ELAcestrant vs. Capecitabine Alone in ER+ Breast Cancer (CAPELA) · Phase 2 · recruiting
NCT07465393 — Facility-Based Multi-Modal Rehab vs. Home-Based Resistance Exercise for Quality of Life in Breast Cancer Survivors · NA · recruiting

Other Shenzhen People's Hospital trials

Trials by the same sponsor.

NCT07512050 — Oral Lactobacillus Reuteri for Skin Barrier Dysfunction in Obesity · NA · not yet recruiting
NCT07366255 — Safety and Efficacy of Tripalmitoleoylglycerol in the Treatment of Dermatitis · NA · completed
NCT07366229 — Topical Application of Engineered Lactobacillus Reuteri With a Zinc Sulfate-Tannic Acid MPN Coating for Acne · Phase 2 · recruiting
NCT07266532 — Topical Lactobacillus Crispatus for Skin Barrier Dysfunction in Obesity · NA · completed
NCT07194200 — Safety and Efficacy of Lactobacillus Plantarum for Psoriasis: A Randomized Double-Blind Placebo-Controlled Trial · Phase 2 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03242551 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Shenzhen People's Hospital
Last refreshed: 14 November 2017

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03242551.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing